Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 7/20 | 0.45 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7422046 | 0.91 | AGTR1 (0.41) | PDE4APDE4BPDE4CPDE4DAGTR1 | |
| SCHEMBL245600 | 0.84 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DAGTR1 | |
| SCHEMBL7421353 | 0.78 | PPARG (0.43) | PDE4APDE4BPDE4CPDE4DAGTR1 | |
| SCHEMBL28826515 | 0.77 | PDE4A (0.41) | PDE4APDE4BPDE4CPDE4DAGTR1 | |
| SCHEMBL244242 | 0.75 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DAGTR1 | |
| SCHEMBL7424013 | 0.71 | AGTR2 (0.46) | AGTR1AGTR2 | |
| SCHEMBL7427913 | 0.69 | AGTR1 (0.44) | AGTR1AGTR2 | |
| SCHEMBL243571 | 0.69 | — | — | |
| SCHEMBL7423304 | 0.68 | PDE4A (0.38) | PDE4APDE4BPDE4CPDE4DAGTR1 | |
| SCHEMBL9434830 | 0.67 | AGTR1 (0.66) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995002596-A1 | AZACYCLIC-HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1995-01-26 | — | — | WO | claimed |
| CN-102861019-B | The medicine for the treatment of or prevention neuropathic pain | NOVARTIS AG (CH) | 2016-05-25 | — | — | CN | disclosed |
| CN-102885818-B | The method for the treatment of or prophylaxis inflammatory pain | NOVARTIS AG (CH) | 2016-05-04 | — | — | CN | disclosed |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | NOVARTIS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| US-9227968-B2 | Method of treatment or prophylaxis of inflammatory pain | NOVARTIS AG (CH) | 2016-01-05 | — | — | US | disclosed |
| US-9018207-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-28 | — | — | US | disclosed |
| US-20140228362-A1 | Method of Treatment or Prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-08-14 | — | — | US | disclosed |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-22 | — | — | US | disclosed |
| US-8722675-B2 | Method of treatment or prophylaxis | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-05-13 | — | — | US | disclosed |
| CN-102049048-B | Method of treatment or prophylaxis | SPINIFEX PHARM PTY LTD | 2013-12-25 | — | — | CN | disclosed |
| US-20090177267-A1 | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2009-07-09 | — | — | US | disclosed |
| CN-101443001-A | Methods of treating or preventing inflammatory pain | UNIV QUEENSLAND (AU) | 2009-05-27 | — | — | CN | disclosed |
| EP-1996183-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-12-03 | — | — | EP | disclosed |
| CN-101087619-A | methods of treatment or prevention | UNIV QUEENSLAND (AU) | 2007-12-12 | — | — | CN | disclosed |
| WO-2007106938-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFLAMMATORY PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-09-27 | — | — | WO | disclosed |
| EP-1830869-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-09-12 | — | — | EP | disclosed |
| US-20060223741-A1 | Method of treatment or prophylaxis | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-10-05 | — | — | US | disclosed |
| WO-2006066361-A1 | METHOD OF TREATMENT OR PROPHYLAXIS | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-06-29 | — | — | WO | disclosed |
| US-5789415-A | Azacyclic-heterocyclic compounds as angiotension II receptor antagonists | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| WO-1995002596-A1 | AZACYCLIC-HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223741-A1 | Method of treatment or prophylaxis | AGTR2, AGTR1, NTSR2 | PDE4A 1314/4885PDE4B 1324/4885PDE4C 2043/4885 |
| US-20160052925-A1 | METHOD OF TREATMENT OR PROPHYLAXIS INFTAMMATORY PAIN | AGTR2, AGTR1, BDKRB2 | PDE4A 2062/4885PDE4B 2250/4885PDE4C 2786/4885 |
| US-20140142116-A1 | Method of Treatment or Prophylaxis of Inflammatory Pain | AGTR2, AGTR1, BDKRB2 | PDE4A 2036/4885PDE4B 2254/4885PDE4C 3317/4885 |
| US-20140228362-A1 | Method of Treatment or Prophylaxis | AGTR2, AGTR1, NTSR2 | PDE4A 1314/4885PDE4B 1324/4885PDE4C 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.